Safety and Immunomodulatory Effects of Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-cell (CD19.CART) Therapy for B-cell Lymphomas: Final Phase I Trial Results
Year: 2026
Type: article
Study design: Clinical Trial
Authors: Nathan Denlinger, NoJoon Song, Negin Goodarzi, Rina Li Welkie, Jungmin Shin, Jordan Krull, Kathleen McConnell, Narendranath Epperla, Jonathan E. Brammer, Yazeed Sawalha, David A. Bond, Evandro Bezerra, John C. Reneau, Audrey M. Sigmund, Yun Choi, Walter Hanel, Lapo Alinari, Polina Shindiapina, Gabriela Sanchez-Petitto, Hannah K. Choe, Sarah Wall, Jiasheng Wang, Chelsea Peterson, Xiaopei Huang, Beth Christian, Sam Penza, Robert Baiocchi, Kami Maddocks, Samantha Jaglowski, Sumithira Vasu, Qin Ma, Dongjung Chung, Mark P Rubinstein, Zihai Li, Marcos de Lima, Paolo Caimi, Timothy Voorhees
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7127371411